Charles River Laboratories International, Inc.
CRL Healthcare Diagnostics & Research
Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024. In the quarter to June 2026, revenue fell 2.72%, EPS fell 102.8%, free cash flow fell 12.2% and total debt rose 12.3%, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow CRL
Charles River Laboratories International, Inc. (CRL) Shares outstanding
Charles River Laboratories International, Inc.'s shares outstanding at the end of fiscal 2025 was $49.6M, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $48.0M. Over the past ten years it has ranged from $47.6M (fiscal 2015) to $51.6M (fiscal 2024); the current reading is higher than 45% of that period. Charles River Laboratories International, Inc. ranks 29th of 52 Diagnostics & Research companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $49.6M | (4.00%) |
| FY2024 | $51.6M | 0.34% |
| FY2023 | $51.5M | 0.29% |
| FY2022 | $51.3M | (0.24%) |
| FY2021 | $51.4M | 1.61% |
| FY2020 | $50.6M | 1.85% |
| FY2019 | $49.7M | 1.38% |
| FY2018 | $49.0M | 0.93% |
| FY2017 | $48.6M | 1.26% |
| FY2016 | $48.0M | 0.68% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $48.0M | (1.90%) |
| Mar 2026 | $49.0M | (1.24%) |
| Dec 2025 | $49.6M | 0.28% |
| Sep 2025 | $49.4M | 0.22% |
| 42 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| QGEN QIAGEN N.V. compare | $207.8M |
| GH Guardant Health, Inc. compare | $132.9M |
| DGX Quest Diagnostics Incorporated compare | $112.0M |
| RVTY Revvity Inc. compare | $111.6M |
| LH Labcorp Holdings Inc. compare | $82.0M |
| ICLR ICON PLC compare | $77.4M |
| TWST Twist Bioscience Corporation compare | $62.4M |
| CRL Charles River Laboratories International, Inc. | $48.0M |
| MEDP Medpace Holdings, Inc. compare | $28.6M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on CRL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement